Immunome Inc. - 8-K Filing
Immunome reported a first-quarter net loss of $53.8 million for the quarter ended March 31, 2026, with research and development expenses at $46.4 million and general and administrative costs at $13.0 million. The company held $582.7 million in cash as of March 31, projecting sufficient funds to support operations through 2028. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $IMNM